Seaport Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Lead programs GlyphAllo and GlyphAgo are advancing through phase II trials, targeting major depressive disorder and generalized anxiety disorder, with key data readouts expected in 2027 and 2028. The Glyph platform enables oral delivery of challenging molecules, and the company is well-funded through 2029.
-
The company presented its neuroscience-focused pipeline, highlighting the Glyph platform's ability to overcome oral bioavailability and liver toxicity issues. Lead programs GlyphAllo and GlyphAgo target depression and anxiety with promising clinical data and registration-enabling trials planned. The platform's versatility and AI-driven efficiencies position it for broader applications.
-
The company presented its neuropsychiatry-focused pipeline, highlighting the Glyph platform's ability to improve oral bioavailability and safety of known drugs. Key milestones include phase II-B and driving study data for GlyphAllo in 2026–2027 and phase II studies for GlyphAgo in 2028, with funding secured into 2029.